Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

  1. Home
  2. Subjects
  3. monoclonal antibodies
monoclonal antibodies
Technique Talk: Analyzing Molecular Interactions During Monoclonal Antibody Development
Technique Talk: Analyzing Molecular Interactions During Monoclonal Antibody Development
The Scientist Creative Services Team in collaboration with Sartorius Corporation | Mar 9, 2021
In this workshop, you will learn how to measure protein interactions using Octet bio-layer interferometry.
A Greener Recombinant Monoclonal Antibody
A Greener Recombinant Monoclonal Antibody
The Scientist Creative Services Team | Dec 9, 2020
Learn more about environmentally-friendly antibodies that deliver superior performance.
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Ashley Yeager | Oct 27, 2020
Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Lisa Winter | Sep 17, 2020
Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.
Bacterial Superglue Enables Antiviral Antibody Discovery
Bacterial Superglue Enables Antiviral Antibody Discovery
Ruth Williams | Jul 13, 2020
Testing out combinations of antiviral proteins from llamas could help researchers create potent virus-neutralizing multimers.
Putting the Brakes on SARS-CoV-2: Neutralizing Antibodies
Putting the Brakes on SARS-CoV-2: Neutralizing Antibodies
The Scientist Creative Services Team | Jul 6, 2020
Experts will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.
First Antibody Trial Launched in COVID-19 Patients
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Chris Baraniuk | Apr 9, 2020
The virus’s tool for prying open host cells is coated in a protective armor of sugar—but gaps may offer vulnerability to disruption by antibodies.
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
Catherine Offord | Oct 14, 2019
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.